risk of recurrent SCD, the largest group at risk is made up of those recovering from acute myocardial infarction. It is this large group of people with a 3% to 8% incidence of sudden death in the first year after infarction and perhaps a 2% to 4% incidence per year thereafter who will be the subject of this article. The questions that need to be addressed are as follows: (1) Do arrhythmias after infarction identify patients at risk for sudden death? (2) Which arrhythmias require therapy because they are potentially "malignant"? (3) How should these arrhythmias be treated?
Identification of patients at risk for sudden death. The most important questionthe one upon which all others are basedis whether spontaneous ventricular arrhythmias during the first 6 weeks after an acute infarction identify patients at risk for sudden death. It has long been hypothesized that ventricular ectopy in this setting predicts those at risk for SCD. Although there is a consensus that, in the absence of ischemia, sustained ventricular tachycardia and fibrillation in the early postinfarction period (within 30 days) require long-term therapy, controversy exists over the role of complex asymptomatic ventricular arrhythmias as predictors of patients who will die suddenly.
Many studies have been performed in patients with coronary artery disease after myocardial infarction and it has been shown that both left ventricular dysfunction and complex ventricular arrhythmias are independent predictors of both total mortality and SCD.1 However, this does not mean that there is a cause and effect relationship between the ventricular arrhythmias and SCD. If a cause and effect relationship were present then the percentage of total deaths that are sudden should be higher in patients with frequent and complex ventricular arrhythmias than in patients without such arrhythmias. The presence of such arrhythmias should yield high sensitivity, specificity, and positive predictive value for SCD. In my opinion, this is not the case.
There are several factors that influence the ability to detect arrhythmias. These include (1) the duration of observationthe longer the period of monitoring, the higher the incidence of arrhythmias, (2) the interval between the recording and the acute infarction the peak time of complex ectopy is 4 to 6 weeks after infarction, (3) the patient population studiedthe percentage of patients with severe left ventricular dysfunction will influence the incidence of arrhythmias, (4) the method of arrhythmia detection computer techniques are better than scanning analog records, and (5) the type of infarction recent data have suggested that arrhythmias may be a more potent predictor of SCD in patients with non-Q wave infarction than in those with transmural infarction. 7 The widely quoted data of Ruberman et al.' (table 1) suggesting that complex arrhythmias are independent predictors of SCD were obtained in a study in which only 1 hr recordings from a group of patients who had suffered infarction a mean of 3 months previously were used. The short time of monitoring and exclusion of patients early after infarction (mortality is highest in the first 6 months after myocardial infarction) limits the utility of these data. Ruberrnan et al. identified 462 patients with complex ventricular arrhythmias as a high-risk group, and 1277 patients without such complex arrhythmias as low-risk patients. Sixty-eight patients (15%) in the high-risk group and 71 patients (6%) in the low-risk group experienced SCD. However, the percentage of total deaths that were sudden was not different in the two groups. Thus, complex ar-rhythmias indicated a group that was at high risk of dying but their mode of death was the same as that in patients in the low-risk group. More importantly, more than half of all patients dying suddenly were from the group of patients without complex arrhythmia. Based on the results of Ruberman, if treatment were attempted based on the presence of complex arrhythmias, 85% of people allegedly at high risk would be inappropriately treated with costly and potentially toxic antiarrhythmic agents, and more than half the patients who were to die suddenly would not be treated.
Results from four studies that evaluated the role of predischarge arrhythmias in predicting sudden death are shown in table 1 .26 Regardless of which arrhythmias defined a "high risk" group, in each study the percentage of total deaths that were sudden did not differ in highand low-risk groups. These studies also demonstrated that predischarge Holter monitoring is a relatively inadequate method for detecting patients who will experience SCD, with a sensitivity of only 25% to 64% and a positive predictive accuracy of less than 20%.
There has been a recent interest in the presence of nonsustained ventricular tachycardia as a marker for sustained tachycardia or fibrillation. The time from the acute infarction at which monitoring is performed markedly influences the incidence of the detection of this arrhythmia. In the critical care unit phase (i.e., within the first 3 days) there may be a 40% incidence of nonsustained ventricular tachycardia. At 4 days the incidence is 5%, and it gradually increases to 10% at 2 weeks, peaking at 15% at 6 weeks. Three studies have been performed which deal with nonsustained ventric- ular tachycardia as a marker for patients at risk of SCD (tables 2 and 3),3,8,9 The incidence of nonsustained ventricular tachycardia ranged from 3.4% to 11.6%. Patients with nonsustained tachycardia had a higher incidence of death (sudden and nonsudden) than those without tachycardia. However, the percent of total deaths that were sudden was similar in both groups. In fact, the ratio of sudden death to total mortality tended to be higher in those patients without ventricular tachycardia. While complex asymptomatic ectopy and left ventricular dysfunction are markers for patients at risk of dying and therefore could be used to select a patient population in whom a controlled trial of antiarrhythmic therapy could be undertaken (see below), the poor sensitivity and predictive value of these arrhythmias for sudden death would still subject many people to unnecessary side effects of drugs. Furthermore, such therapy would fail to prevent sudden death in half the patients destined to die suddenly, even if that drug prevented 100% of the sudden deaths in the so-called high-risk population, a feat that is highly unlikely. If we had drugs that were effective, inexpensive, had no side effects, and were nonarrhythmogenic, perhaps these factors would be less important and everyone could be treated after acute infarction. Obviously no such agent is available.
A particular problem that has received less attention is sustained ventricular tachycardia and/or cardiac arrest in the first 6 weeks after myocardial infarction. This occurs in 2% to 4% of patients after acute infarction and in our experience has a peak incidence in the second and third week. A recent study by Braat et al.'°h as shown that no frequency or morphologic characteristic of ventricular arrhythmias predicts the occurrence of this event. Extensive anterior infarction, congestive heart failure, and the presence of right bundle branch block during the acute infarction were seen in 75%, 100%, and 30%, respectively, of patients who developed ventricular tachycardia. In addition, 88% had left ventricular aneurysms and markedly depressed ejection fractions ranging from 9% to 35%. Up to 35% of patients with these clinical findings will develop sustained ventricular arrhythmias. Most (84%) arrhythmias occurred within the first 2 weeks and 56% of such patients were dead within 3 months. Such patients should be monitored for longer periods of time (e.g., 3 to 4 weeks) before discharge from the hospital.
Which arrhythmias require therapy? Based on the prior discussion I do not believe that asymptomatic arrhythmias recorded at the time of discharge after acute infarction should be treated since (1) they have a low sensitivity and poor predictive accuracy of selecting patients at risk for SCD, and (2) antiarrhythmic therapy in such patients has not been shown to prevent SCD. This stance may be considered by some to be too puristic since it is at variance with common clinical practice. It is, however, a position that is better supported by the data than one in which treatment of asymptomatic ectopy is undertaken. There is, however, little argument over treating symptomatic arrhythmias; how to treat them is the major problem.
How to treat arrhythmias. There have been no convincing studies showing a benefit to patients treated with empiric antiarrhythmic drugs for asymptomatic arrhythmias. Two probable reasons for this finding are that (1) treatment of asymptomatic arrhythmias actually does not improve prognosis because these arrhythmias are not specifically and causally related to SCD and (2) antiarrhythmic therapy may prevent SCD in some patients, but their proarrhythmic effects initiate sudden death in other patients, resulting in no overall effect. Thus, at our institution we do not believe asymptomatic arrhythmias should be treated and no form of antiarrhythmic therapy is routinely given for such arrhythmias.
There are three basic approaches to antiarrhythmic therapy, should it be given: empiric therapy, therapy guided by Holter monitoring, and therapy guided by electrophysiologic studies. In patients with symptomatic arrhythmias that are not life-threatening the major goal of therapy is to diminish symptoms. Abolition of symptoms alone may suffice in judging the efficacy of antiarrhythmic therapy. For symptomatic ectopy, in-cluding short (<4 beat) runs of nonsustained ventricular tachycardia, we usually initiate therapy with /Bblockers. These agents have a twofold benefit. First, they are anti-ischemic, and second, they can reduce symptoms in patients regardless of their effect on ventricular ectopic activity, possibly by a sedative effect. Furthermore, such agents have been shown to diminish ventricular ectopic activity, particularly that occurring in the daytime, in patients after infarction.
Another group of patients are those with frequent and more prolonged episodes of nonsustained tachycardia, particularly polymorphic ventricular tachycardia. Syncope or presyncope may be the presenting symptom in this group. When episodes of rapid nonsustained tachycardia occur in the setting of massive anterior infarction and begin in the second week after infarction, they may be a harbinger of lethal ventricular tachycardia/fibrillation. Such patients require more rigorous drug selection and evaluation. Our recommendations on the therapeutic approach to such patients reflect a personal bias. For those patients who have very frequent nonsustained tachycardias associated with symptoms, Holter monitoring can be used for evaluation of antiarrhythmic efficacy. The goals in this instance would be to abolish the prolonged symptomatic tachycardias. Abolition of lesser ventricular complex ectopy is unnecessary.
When the frequency of arrhythmias is low, then Holter monitoring cannot be used to quantitate their frequency and evaluate antiarrhythmic therapy. This is due to the marked spontaneous variability, over the short and long term, of both simple and complex arrhythmias in patients with coronary artery disease. In such instances programmed stimulation is a more appropriate method of arriving at safe drug therapy. No good data exist, however, confirming the effectiveness of either method in prolonging survival in such patients.
Electrophysiologic testing has been used to select antiarrhythmic therapy successfully in patients with chronic recurrent ventricular tachycardia and in patients who are survivors of cardiac arrest. Antiarrhythmic therapy based on electrophysiologic testing has improved survival in these patients. Thus, in patients who have sustained ventricular tachycardia or cardiac arrest, or infrequent symptomatic nonsustained tachycardia in the peri-infarction period, we recommend therapy guided by electrophysiologic testing. If a sustained monomorphic tachycardia is induced, antiarrhythmic therapy can be administered based on the results of electrophysiologic testing. Usually procaina-mide or a type I agent is the first drug used and such an agent singly or in combination with another currently approved drug is effective in approximately half the patients in whom it is tested. In addition, at the time of the electrophysiologic study it may be possible to map the tachycardia and localize the arrhythmogenic area responsible for it.
In our experience, patients who have spontaneous sustained ventricular tachycardia in the peri-infarction period fall into two groups. One group is those with modest-sized infarctions who have a single episode of ventricular tachycardia. These patients frequently respond to antiarrhythmic agents and have a relatively good prognosis over the next 12 months. A second group of patients with larger infarctions (usually anterior) who present with congestive heart failure and often (up to 30% of the time) right bundle branch block have recurrent episodes of tachycardia that cannot be effectively treated with antiarrhythmic agents, including amiodarone. There is a growing appreciation for the fact that these patients have such a high mortality that surgery offers the only viable option that can treat their severe left ventricular dysfunction, remaining coronary abnormalities, and the electrophysiologic substrate produced by the infarction. We believe that in the absence of surgical intervention at least 80% of these patients will be dead within the first year. Thus, at our institution all of these patients undergo electrophysiologic studies in an attempt to localize either the tachycardia and/or areas of abnormal electrical activity that suggest an abnormal electrophysiologic substrate. Surgical therapy includes aneurysmectomy (present >80% of the time) or infarctectomy and endocardial resection with or without adjunctive cryoablation based on activation mapping in the operating room. These tachycardias, which are often too rapid to map in the catheter laboratory, can be mapped intraoperatively. Some form of mapping is mandatory since a well-defined scar may be absent. The results of surgical therapy in these patients are gratifying. At our institution the operative mortality of patients operated on within the first 2 months after infarction has been approximately 20%, but we have observed no recurrences of arrhythmias and improved hemodynamics in the year after surgery. We therefore believe that patients with recurrent episodes of ventricular tachycardia in the first 6 weeks after infarction should be considered operative candidates and be managed accordingly as the first method of therapy. In those patients who have a single episode of uniform ventricular tachycardia, electrophysiologic studies with a goal of appropriate pharmacologic therapy should be tried first.
It must, however, be reiterated that there have been no large controlled studies demonstrating an improved survivorship when therapy is based on either Holter monitoring or electrophysiologic testing. However, in patients with prior infarction a good correlation between responsiveness to drug testing by electrophysiologic studies and clinical outcome has been reported in several uncontrolled series.1-13 A single uncontrolled study has shown a good correlation of response to antiarrhythmic therapy based on Holter monitoring to clinical outcome.14 I strongly believe that when arrhythmias are to be treated, it should be done nonempirically, by either a noninvasive or an invasive approach. The role of surgery in the management of sustained arrhythmias appears justified but further studies are necessary to confirm this.
Future directions. The important goal for the prevention of SCD after infarction is to develop more sensitive and predictive criteria to identify patients at risk. Large, expensive multicenter trials evaluating drug therapy of postinfarction arrhythmias (The Cardiac Arrhythmia Pilot Study or CAPS'5) ignore a significant body of data. Such studies will not help our understanding of the mechanisms of SCD, will not improve our ability to select patients at risk, and will take financial support away from, and thus delay, the more important task of better identification of patients at risk. Most people will be unnecessarily treated and half the people at risk will not be treated.
Methods that are being evaluated to add to our ability to predict patients at risk include signal-averaged electrocardiography and fast-Fourier transform of the electrocardiogram, both of which attempt to look at frequency, amplitude, and time-duration parameters of ventricular activation as markers for risk of ventricular tachycardia and fibrillation. 6' 17 Preliminary data show that 15% to 25% of patients have such markers. Whether such markers alone or in combination with other clinical electrophysiologic data will be useful awaits further study.
Programmed stimulation has been used in an attempt to identify patients at risk. Much conflicting data exist, however, regarding the significance of inducible sustained ventricular tachycardia or fibrillation as a marker.'20 Our data show no utility of programmed electrical stimulation.'8 However, the combination of induction of sustained arrhythmias with programmed electrical stimulation and an abnormal signal-averaged electrocardiogram may be useful. At least one study20 shows a 33% incidence of clinical sustained ventricular tachycardia if sustained monomorphic tachycardia at a rate of less than 250 beats/min is induced in the presence of a late potential.
The problem of treatment remains even if we identify high-risk patients. Antiarrhythmics with proven efficacy, no proarrhythmic potential, and no side effects that are easy to take are not available. It is unlikely that any single drug can be manufactured that can alter all the potential initiating and sustaining mechanisms of SCD. The potential for electronic devices is great. The current automatic internal cardioverter-defibrillator can abort SCD but is too large, too short-lived, and requires improved sensing and charging capability to be widely used. However, if miniaturized devices that are more durable and have better sensing algorithms are developed, they may supplant drugs as a method of preventing SCD. They will not, however, alter the underlying mechanisms. Special types of surgical procedures in appropriately selected patients offer the only hope of removing the substrate responsible for SCD. Identifying such patients and deciding on the type and time of surgery has not been resolved.
Conclusions. Prevention of sudden death remains a major objective in all patients after infarction. Since no drug is uniformly effective in preventing SCD, is free of side effects, and is not proarrhythmic, it is unethical to expose the large population at risk to the expense and side effects of such drugs. It is obvious that all arrhythmias need not be treated. It is imperative that one always keep in mind the Eleventh Commandment: "Thou shall not make the treatment worse than the disease." In order to do this one should always treat only those arrhythmias that have a high likelihood of lethality, to remove reversible factors producing arrhythmias, and to utilize rigorous methods that are able to accurately identify the presence of the lethal arrhythmia and efficacy of the therapy. Much progress is needed but restraint is also necessary.
